Harrow Announces Third Quarter 2025 Financial Results
Harrow (Nasdaq: HROW) reported Q3 2025 total revenues of $71.6 million, a 45% increase versus $49.3 million in Q3 2024, and adjusted EBITDA of $22.7 million. GAAP net income for the quarter was $1.0 million and cash and cash equivalents were $74.3 million as of September 30, 2025.
Operational highlights include new national payer coverage agreements for VEVYE effective January 1, 2026, expansion of the VEVYE Access For All program via a partnership with Alto Pharmacy Powered by Fuze Health, the launch of Harrow Access for All (HAFA), and an agreement to acquire Melt Pharmaceuticals, maker of MELT-300.
Harrow (Nasdaq: HROW) ha riportato ricavi totali nel terzo trimestre 2025 di 71,6 milioni di dollari, con un incremento del 45% rispetto ai 49,3 milioni di dollari nel Q3 2024, e un EBITDA rettificato di 22,7 milioni di dollari. l’utile netto GAAP per il trimestre è stato di 1,0 milioni di dollari e la liquidità e le disponibilità liquide ammontavano a 74,3 milioni di dollari al 30 settembre 2025.
Tra gli highlight operativi vi sono nuovi accordi di copertura nazionale da parte dei payer per VEVYE, effective 1 gennaio 2026, l’espansione del programma VEVYE Access For All tramite una partnership con Alto Pharmacy Powered by Fuze Health, il lancio di Harrow Access for All (HAFA) e un accordo per l’acquisizione di Melt Pharmaceuticals, produttore di MELT-300.
Harrow (Nasdaq: HROW) informó ingresos totales del tercer trimestre de 2025 de 71,6 millones de dólares, un aumento del 45% frente a los 49,3 millones de dólares en el Q3 de 2024, y un EBITDA ajustado de 22,7 millones de dólares. La utilidad neta GAAP del trimestre fue de 1,0 millón de dólares y las existencias y equivalentes de efectivo fueron de 74,3 millones de dólares al 30 de septiembre de 2025.
Entre los aspectos operativos destacados se incluyen nuevos acuerdos de cobertura de pagadores a nivel nacional para VEVYE, con efecto a partir del 1 de enero de 2026, la expansión del programa VEVYE Access For All mediante una asociación con Alto Pharmacy Powered by Fuze Health, el lanzamiento de Harrow Access for All (HAFA) y un acuerdo para adquirir Melt Pharmaceuticals, fabricante de MELT-300.
Harrow (Nasdaq: HROW)는 2025년 3분기 총매출이 7,160만 달러로, 2024년 3분기의 4,930만 달러 대비 45% 증가했고, 조정 EBITDA는 2,270만 달러였습니다. 분기의 GAAP 순이익은 100만 달러였고, 2025년 9월 30일 기준 현금 및 현금성자산은 7,430만 달러였습니다.
운영 하이라이트로는 2026년 1월 1일 효력을 발휘하는 VEVYE에 대한 새로운 전국적 지불자 보장 계약, Fuze Health가 지원하는 Alto Pharmacy와의 파트너십을 통한 VEVYE Access For All 프로그램의 확장, Harrow Access for All(HAFA)의 출시, MELT-300의 제조사 Melt Pharmaceuticals를 인수하는 합의가 포함됩니다.
Harrow (Nasdaq : HROW) a annoncé un chiffre d’affaires total du T3 2025 de 71,6 millions de dollars, soit une hausse de 45 % par rapport à 49,3 millions de dollars au T3 2024, et un EBITDA ajusté de 22,7 millions de dollars. Le résultat net GAAP pour le trimestre s’est élevé à 1,0 million de dollars, et la trésorerie et équivalents de trésorerie s’élevaient à 74,3 millions de dollars au 30 septembre 2025.
Les points marquants opérationnels incluent de nouveaux accords nationaux de couverture par les payeurs pour VEVYE à compter du 1er janvier 2026, l’expansion du programme VEVYE Access For All via un partenariat avec Alto Pharmacy Powered by Fuze Health, le lancement de Harrow Access for All (HAFA) et un accord pour acquérir Melt Pharmaceuticals, fabricant de MELT-300.
Harrow (Nasdaq: HROW) meldete Gesamterlöse im Q3 2025 von 71,6 Millionen USD, eine Steigerung von 45% gegenüber 49,3 Millionen USD im Q3 2024, und ein bereinigtes EBITDA von 22,7 Millionen USD. Das GAAP-Nettoeinkommen für das Quartal betrug 1,0 Million USD und Barbestände sowie Gleichwertiges beliefen sich zum 30. September 2025 auf 74,3 Millionen USD.
Zu den operativen Highlights gehören neue landesweite Abdeckungsverträge der Zahlungsträger für VEVYE mit Wirkung zum 1. Januar 2026, die Erweiterung des VEVYE Access For All-Programms durch eine Partnerschaft mit Alto Pharmacy powered by Fuze Health, der Start von Harrow Access for All (HAFA) und eine Vereinbarung zum Erwerb von Melt Pharmaceuticals, Hersteller von MELT-300.
Harrow (Nasdaq: HROW) أعلنت عن إيرادات إجمالية للربع الثالث من 2025 قدرها 71.6 مليون دولار، بزيادة قدرها 45% مقارنة بـ 49.3 مليون دولار في الربع الثالث من 2024، و EBITDA المعدّل قدره 22.7 مليون دولار. صافي الدخل وفق المعايير GAAP للربع كان 1.0 مليون دولار، والسيولة النقدية وما يعادلها كانت 74.3 مليون دولار حتى 30 سبتمبر 2025.
أهم النقاط التشغيلية تشمل اتفاقيات تغطية وطنية من قبل الجهات الدافعة للشراء لـ VEVYE اعتباراً من 1 يناير 2026، وتوسيع برنامج VEVYE Access For All من خلال شراكة مع Alto Pharmacy Powered by Fuze Health، وإطلاق Harrow Access for All (HAFA)، واتفاقية للاستحواذ على Melt Pharmaceuticals، الشركة المصنعة لـ MELT-300.
- Revenue +45% to $71.6M in Q3 2025
- Adjusted EBITDA of $22.7M for Q3 2025
- Cash of $74.3M as of September 30, 2025
- VEVYE coverage wins effective Jan 1, 2026
- Signed agreement to acquire Melt Pharmaceuticals
- Nine-month cumulative net loss $(11.8)M through Sept 30, 2025
- GAAP net income of $1.0M is small relative to revenue growth
Insights
Strong revenue growth, positive GAAP net income and sizable Adjusted EBITDA mark a materially improved quarter for the company.
The company reported total revenues of
Key dependencies and risks include the timing and impact of newly announced commercial and access initiatives: VEVYE coverage wins that are expected to take preferred formulary effect on
Concrete items to watch in the near term are the integration progress and deal terms of the Melt acquisition, the actual formulary placements and utilization beginning
Third-Quarter 2025 and Recent Selected Highlights:
- Total revenues of
$71.6 million , a45% increase over$49.3 million recorded in the prior-year period - GAAP net income of
$1.0 million - Adjusted EBITDA of
$22.7 million - Cash and cash equivalents of
$74.3 million as of September 30, 2025
A Media Snippet accompanying this announcement is available by clicking on this link.
NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for the business.
“The third quarter represented another period of meaningful progress for Harrow. We continued to execute across our portfolio, driving strong performance from VEVYE® and IHEEZO®, while advancing several strategic initiatives that strengthen our foundation for future growth,” said Mark L. Baum, Chief Executive Officer of Harrow. “With the launch of TRIESENCE® into its largest market opportunity, the upcoming rollout of our Harrow Access for All (HAFA) program, the expansion of our commercial leadership team, and new major coverage wins for VEVYE, we are well-positioned for a terrific close to the year and sustained growth for many years to come.
Business Highlights:
- Coverage Expansion for VEVYE
- Harrow recently entered into coverage agreements with several leading national payers, including the largest US pharmacy benefit manager of commercial lives. As a result of these coverage wins, VEVYE is expected to be included on multiple new formulary listings with a preferred product status effective January 1, 2026.
- Expands VEVYE Access For All (VAFA) Program Capacity Through Partnership with Alto Pharmacy Powered by Fuze Health
- Harrow has entered into a partnership with Alto Pharmacy Powered by Fuze Health, a full-service, digitally powered pharmacy, marking the addition of Harrow’s third specialty pharmacy partner supporting the VAFA program. This strategic expansion significantly expands its national distribution footprint via Alto’s comprehensive pharmacy network. Alto’s coverage model, ability to communicate in over 250 languages, and retail infrastructure, should enable broader insurance coverage, improve affordability, and expand patient access.
- Melt Acquisition
- In September 2025, Harrow announced that it had entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of a fixed dose of midazolam (3mg) and ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. This innovative approach has the potential to transform patient experiences across a wide range of office-based and outpatient procedures and address the healthcare system’s growing demand to reduce exposure to opioids.
- Harrow Access for All
- In September 2025, Harrow announced the launch of Harrow Access for All (HAFA), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full range of branded, generic, and compounded ophthalmic medications. HAFA builds on the success of the VEVYE® Access for All initiative, which launched in March 2025 with a strong reception from both physicians and patients.
Third Quarter 2025 Financial Results:
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Total revenues | $ | 71,638,000 | $ | 49,257,000 | $ | 183,211,000 | $ | 132,783,000 | ||||||||
| Gross margin | 75 | % | 76 | % | 73 | % | 74 | % | ||||||||
| Core gross margin(1) | 81 | % | 80 | % | 79 | % | 78 | % | ||||||||
| Net income (loss) | 1,020,000 | (4,220,000 | ) | (11,765,000 | ) | (24,258,000 | ) | |||||||||
| Core net income (loss)(1) | 12,933,000 | (1,619,000 | ) | 8,606,000 | (13,455,000 | ) | ||||||||||
| Adjusted EBITDA(1) | 22,732,000 | 8,808,000 | 37,753,000 | 17,838,000 | ||||||||||||
| Net income (loss) per share: | ||||||||||||||||
| Basic | 0.03 | (0.12 | ) | (0.32 | ) | (0.68 | ) | |||||||||
| Diluted | 0.03 | (0.12 | ) | (0.32 | ) | (0.68 | ) | |||||||||
| Core net income (loss) per share:(1) | ||||||||||||||||
| Basic | 0.35 | (0.05 | ) | 0.24 | (0.38 | ) | ||||||||||
| Diluted | 0.33 | (0.05 | ) | 0.24 | (0.38 | ) | ||||||||||
(1) Core gross margin, core net income (loss), core basic and diluted net income (loss) per share (collectively, “Core Results”), and Adjusted EBITDA are non-GAAP measures. For additional information, including a reconciliation of such Core Results and Adjusted EBITDA to the most directly comparable measures presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation tables at the end of this release.
Conference Call and Webcast
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward--looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, refinance and otherwise service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking- statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking- statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Contact:
Mike Biega, VP of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890
| HARROW, INC. CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
| September 30, 2025 | December 31, 2024 | ||||
| (unaudited) | |||||
| ASSETS | |||||
| Cash and cash equivalents | $ | 74,290,000 | $ | 47,247,000 | |
| All other current assets | 103,314,000 | 142,404,000 | |||
| Total current assets | 177,604,000 | 189,651,000 | |||
| All other assets | 185,470,000 | 199,320,000 | |||
| TOTAL ASSETS | $ | 363,074,000 | $ | 388,971,000 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
| Current liabilities | $ | 65,400,000 | $ | 91,343,000 | |
| Loans payable, net of unamortized debt discount | 242,874,000 | 219,539,000 | |||
| All other liabilities | 8,139,000 | 8,792,000 | |||
| TOTAL LIABILITIES | 316,413,000 | 319,674,000 | |||
| TOTAL STOCKHOLDERS' EQUITY | 46,661,000 | 69,297,000 | |||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 363,074,000 | $ | 388,971,000 | |
| HARROW, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Total revenues | $ | 71,638,000 | $ | 49,257,000 | $ | 183,211,000 | $ | 132,783,000 | |||||||
| Cost of sales | 17,712,000 | 12,018,000 | 49,466,000 | 35,110,000 | |||||||||||
| Gross profit | 53,926,000 | 37,239,000 | 133,745,000 | 97,673,000 | |||||||||||
| Selling, general and administrative | 35,856,000 | 33,645,000 | 109,604,000 | 94,275,000 | |||||||||||
| Research and development | 3,323,000 | 2,273,000 | 9,217,000 | 7,475,000 | |||||||||||
| Total operating expenses | 39,179,000 | 35,918,000 | 118,821,000 | 101,750,000 | |||||||||||
| Income (loss) from operations | 14,747,000 | 1,321,000 | 14,924,000 | (4,077,000 | ) | ||||||||||
| Total other expense, net | (13,727,000 | ) | (5,521,000 | ) | (26,689,000 | ) | (19,506,000 | ) | |||||||
| Income tax expense | - | 20,000 | - | 675,000 | |||||||||||
| Net income (loss) | $ | 1,020,000 | $ | (4,220,000 | ) | $ | (11,765,000 | ) | $ | (24,258,000 | ) | ||||
| Net income (loss) per share: | |||||||||||||||
| Basic | $ | 0.03 | $ | (0.12 | ) | $ | (0.32 | ) | $ | (0.68 | ) | ||||
| Diluted | $ | 0.03 | $ | (0.12 | ) | $ | (0.32 | ) | $ | (0.68 | ) | ||||
| HARROW, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| For the Nine Months Ended September 30, | |||||||
| 2025 | 2024 | ||||||
| Net cash provided by (used in): | |||||||
| Operating activities | $ | 35,453,000 | $ | (4,423,000 | ) | ||
| Investing activities | (730,000 | ) | 4,396,000 | ||||
| Financing activities | (7,680,000 | ) | (1,457,000 | ) | |||
| Net change in cash and cash equivalents | 27,043,000 | (1,484,000 | ) | ||||
| Cash and cash equivalents at beginning of the period | 47,247,000 | 74,085,000 | |||||
| Cash and cash equivalents at end of the period | $ | 74,290,000 | $ | 72,601,000 | |||
Non-GAAP Financial Measures
In addition to the Company’s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA and Core Results, unaudited financial measures that are not calculated in accordance with GAAP, to evaluate the Company’s financial results and performance and to plan and forecast future periods. Adjusted EBITDA and Core Results are considered “non-GAAP” financial measures within the meaning of Regulation G promulgated by the SEC. Management believes that these non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, provide a more complete understanding of the Company’s results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA and Core Results provide meaningful supplemental information regarding the Company’s performance because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) they exclude the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance; and (iii) they are used by institutional investors and the analyst community to help analyze the Company’s results. However, Adjusted EBITDA, Core Results, and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors.
Adjusted EBITDA
The Company defines Adjusted EBITDA as net income (loss), excluding the effects of stock-based compensation and expenses, interest, taxes, depreciation, amortization, investment loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.
The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss), for the three months and nine months ended September 30, 2025 and for the same period in 2024:
| HARROW, INC. RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| GAAP net income (loss) | $ | 1,020,000 | $ | (4,220,000 | ) | $ | (11,765,000 | ) | $ | (24,258,000 | ) | ||||
| Stock-based compensation and expenses | 3,271,000 | 4,385,000 | 8,702,000 | 12,825,000 | |||||||||||
| Interest expense, net | 6,038,000 | 5,525,000 | 18,994,000 | 16,411,000 | |||||||||||
| Income tax expense | - | 20,000 | - | 675,000 | |||||||||||
| Depreciation | 490,000 | 497,000 | 1,451,000 | 1,382,000 | |||||||||||
| Amortization of intangible assets | 4,224,000 | 2,605,000 | 12,676,000 | 7,708,000 | |||||||||||
| Investment loss, net | - | - | - | 3,171,000 | |||||||||||
| Other expense (income), net | 7,689,000 | (4,000 | ) | 7,695,000 | (76,000 | ) | |||||||||
| Adjusted EBITDA | $ | 22,732,000 | $ | 8,808,000 | $ | 37,753,000 | $ | 17,838,000 | |||||||
Core Results
Harrow Core Results, including core gross margin, core net income (loss), and core basic and diluted income (loss) per share exclude (1) all amortization and impairment charges of intangible assets, excluding software development costs, (2) net gains and losses on investments and equity securities, including equity method gains and losses and equity valued at fair value through profit and loss (FVPL), and preferred stock dividends, and (3) gains/losses on forgiveness of debt. In certain periods, Core Results may also exclude fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, obligations related to product recalls, certain acquisition-related items, restructuring charges/releases and associated items, related legal items, gains/losses on early extinguishment of debt or debt modifications, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a
The following is a reconciliation of Core Results, non-GAAP measures, to the most comparable GAAP measures for the three months and nine months ended September 30, 2025 and 2024:
| For the Three Months Ended September 30, 2025 | |||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | |||||||||||||||
| Gross profit | $ | 53,926,000 | $ | 3,780,000 | $ | - | $ | - | $ | 57,706,000 | |||||||||
| Gross margin | 75 | % | 81 | % | |||||||||||||||
| Operating income | 14,747,000 | 4,224,000 | - | - | 18,971,000 | ||||||||||||||
| Income before taxes | 1,020,000 | 4,224,000 | - | 7,689,000 | 12,933,000 | ||||||||||||||
| Taxes | - | - | - | - | - | ||||||||||||||
| Net income | 1,020,000 | 4,224,000 | - | 7,689,000 | 12,933,000 | ||||||||||||||
| Income per share ($)(1): | |||||||||||||||||||
| Basic | 0.13 | 0.35 | |||||||||||||||||
| Diluted | 0.13 | 0.33 | |||||||||||||||||
| Weighted average number of shares of common stock outstanding: | |||||||||||||||||||
| Basic | 37,145,440 | 37,145,440 | |||||||||||||||||
| Diluted | 38,875,005 | 38,875,005 | |||||||||||||||||
| For the Nine Months Ended September 30, 2025 | |||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | |||||||||||||||
| Gross profit | $ | 133,745,000 | $ | 11,340,000 | $ | - | $ | - | $ | 145,085,000 | |||||||||
| Gross margin | 73 | % | 79 | % | |||||||||||||||
| Operating income | 14,924,000 | 12,676,000 | - | - | 27,600,000 | ||||||||||||||
| Loss before taxes | (11,765,000 | ) | 12,676,000 | 7,695,000 | 8,606,000 | ||||||||||||||
| Taxes | - | - | - | - | - | ||||||||||||||
| Net loss | (11,765,000 | ) | 12,676,000 | - | 7,695,000 | 8,606,000 | |||||||||||||
| Basic and diluted loss per share ($)(1) | (0.32 | ) | (0.24 | ) | |||||||||||||||
| Weighted average number of shares of common stock outstanding, basic and diluted | 36,588,163 | 36,588,163 | |||||||||||||||||
| For the Three Months Ended September 30, 2024 | |||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | |||||||||||||||
| Gross profit | $ | 37,239,000 | $ | 2,191,000 | $ | - | $ | - | $ | 39,430,000 | |||||||||
| Gross margin | 76 | % | 80 | % | |||||||||||||||
| Operating income | 1,321,000 | 2,605,000 | - | - | 3,926,000 | ||||||||||||||
| (Loss) income before taxes | (4,200,000 | ) | 2,605,000 | - | (4,000 | ) | (1,599,000 | ) | |||||||||||
| Taxes | (20,000 | ) | - | - | - | (20,000 | ) | ||||||||||||
| Net (loss) income | (4,220,000 | ) | 2,605,000 | - | (4,000 | ) | (1,619,000 | ) | |||||||||||
| Basic and diluted loss per share ($)(1) | (0.12 | ) | (0.05 | ) | |||||||||||||||
| Weighted average number of shares of common stock outstanding, basic and diluted | 35,702,200 | 35,702,200 | |||||||||||||||||
| For the Nine Months Ended September 30, 2024 | |||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | |||||||||||||||
| Gross profit | $ | 97,673,000 | $ | 6,471,000 | $ | - | $ | - | $ | 104,144,000 | |||||||||
| Gross margin | 74 | % | 78 | % | |||||||||||||||
| Operating loss | (4,077,000 | ) | 7,708,000 | - | - | 3,631,000 | |||||||||||||
| (Loss) income before taxes | (23,583,000 | ) | 7,708,000 | 3,171,000 | (76,000 | ) | (12,780,000 | ) | |||||||||||
| Taxes | (675,000 | ) | - | - | - | (675,000 | ) | ||||||||||||
| Net (loss) income | (24,258,000 | ) | 7,708,000 | 3,171,000 | (76,000 | ) | (13,455,000 | ) | |||||||||||
| Basic and diluted loss per share ($)(1) | (0.68 | ) | (0.38 | ) | |||||||||||||||
| Weighted average number of shares of common stock outstanding, basic and diluted | 35,597,409 | 35,597,409 | |||||||||||||||||
(1) Core basic and diluted loss per share is calculated using the weighted-average number of shares of common stock outstanding during the period. Core basic and diluted loss per share also contemplates dilutive shares associated with equity based awards as described in Note 2 and elsewhere in the Consolidated Financial Statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
FAQ
What were Harrow's (HROW) Q3 2025 revenues and growth rate?
How much adjusted EBITDA did Harrow (HROW) report for Q3 2025?
What is the timing of VEVYE coverage expansions for HROW patients?
What acquisition did Harrow (HROW) announce in September 2025?
How much cash did Harrow (HROW) have at quarter end?
What is Harrow Access for All (HAFA) and when was it launched?
Did Harrow (HROW) report a net profit for Q3 2025?
